Pacific Biosciences of California (PACB) Stock Falls 6.67% Amidst S&P 500's 1.67% Loss: Key Insights

viernes, 27 de marzo de 2026, 7:19 pm ET1 min de lectura
PACB--

Pacific Biosciences of California (PACB) stock fell 6.67% to $1.26, trailing the S&P 500's 1.67% loss. Analysts expect EPS of -$0.17 and revenue of $41 million, with a Zacks Rank of #1 (Strong Buy). The Medical - Instruments industry ranks 94th out of 250 industries and is expected to outperform.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios